23 May 2013
Keywords: tovaxin, trial, completes, patient, enrollment, texas, usa-based
Article | 28 May 2007
Texas, USA-based cell-therapy developer Opexa Therapeutics says it has completed patient enrollment in a Phase IIb study of Tovaxin, its
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 May 2007
21 May 2007
© 2013 thepharmaletter.com